MBOT News & Events

Microbot Medical announced that the Company, both in the USA and in Israel, is not experiencing any business disruption as a result of current geopolitical events. The safety and security of the employees remain its top priority. All personnel continue to operate as usual, and both internal operations and the lead manufacturing partner remain fully functional. Following the recent FDA clearance of LIBERTY, the commercial focus of the Company has been on the U.S. market, managed by its dedicated U.S.-based commercial team headquartered in Hingham, MA. This ensures uninterrupted service, reliable distribution, and continued advancement of the limited market release of the LIBERTY System as planned. The Company maintains sufficient inventory in the U.S. to support current customers and is actively building additional stock through its U.S.-based third-party logistics partner to meet anticipated demand.

Microbot Medical announced that Tampa General Hospital has become the first health system in Florida to adopt LIBERTY, marking a milestone following the Company's recent FDA 510(k) clearance. Microbot believes that this reflects early post-clearance momentum for LIBERTY and highlights growing institutional readiness for advanced robotic solutions in peripheral endovascular procedures.